Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28


Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.

AbuHammad S, Cullinane C, Martin C, Bacolas Z, Ward T, Chen H, Slater A, Ardley K, Kirby L, Chan KT, Brajanovski N, Smith LK, Rao AD, Lelliott EJ, Kleinschmidt M, Vergara IA, Papenfuss AT, Lau P, Ghosh P, Haupt S, Haupt Y, Sanij E, Poortinga G, Pearson RB, Falk H, Curtis DJ, Stupple P, Devlin M, Street I, Davies MA, McArthur GA, Sheppard KE.

Proc Natl Acad Sci U S A. 2019 Sep 3;116(36):17990-18000. doi: 10.1073/pnas.1901323116. Epub 2019 Aug 22.


First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study.

Khot A, Brajanovski N, Cameron DP, Hein N, Maclachlan KH, Sanij E, Lim J, Soong J, Link E, Blombery P, Thompson ER, Fellowes A, Sheppard KE, McArthur GA, Pearson RB, Hannan RD, Poortinga G, Harrison SJ.

Cancer Discov. 2019 Aug;9(8):1036-1049. doi: 10.1158/2159-8290.CD-18-1455. Epub 2019 May 15.


Changes in long-range rDNA-genomic interactions associate with altered RNA polymerase II gene programs during malignant transformation.

Diesch J, Bywater MJ, Sanij E, Cameron DP, Schierding W, Brajanovski N, Son J, Sornkom J, Hein N, Evers M, Pearson RB, McArthur GA, Ganley ARD, O'Sullivan JM, Hannan RD, Poortinga G.

Commun Biol. 2019 Jan 28;2:39. doi: 10.1038/s42003-019-0284-y. eCollection 2019.


Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.

Martin CA, Cullinane C, Kirby L, Abuhammad S, Lelliott EJ, Waldeck K, Young RJ, Brajanovski N, Cameron DP, Walker R, Sanij E, Poortinga G, Hannan RD, Pearson RB, Hicks RJ, McArthur GA, Sheppard KE.

Int J Cancer. 2018 May 15;142(10):2139-2152. doi: 10.1002/ijc.31220. Epub 2018 Jan 3.


Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population.

Hein N, Cameron DP, Hannan KM, Nguyen NN, Fong CY, Sornkom J, Wall M, Pavy M, Cullinane C, Diesch J, Devlin JR, George AJ, Sanij E, Quin J, Poortinga G, Verbrugge I, Baker A, Drygin D, Harrison SJ, Rozario JD, Powell JA, Pitson SM, Zuber J, Johnstone RW, Dawson MA, Guthridge MA, Wei A, McArthur GA, Pearson RB, Hannan RD.

Blood. 2017 May 25;129(21):2882-2895. doi: 10.1182/blood-2016-05-718171. Epub 2017 Mar 10.


Selective inhibition of RNA polymerase I transcription as a potential approach to treat African trypanosomiasis.

Kerry LE, Pegg EE, Cameron DP, Budzak J, Poortinga G, Hannan KM, Hannan RD, Rudenko G.

PLoS Negl Trop Dis. 2017 Mar 6;11(3):e0005432. doi: 10.1371/journal.pntd.0005432. eCollection 2017 Mar.


Genomic characterisation of Eμ-Myc mouse lymphomas identifies Bcor as a Myc co-operative tumour-suppressor gene.

Lefebure M, Tothill RW, Kruse E, Hawkins ED, Shortt J, Matthews GM, Gregory GP, Martin BP, Kelly MJ, Todorovski I, Doyle MA, Lupat R, Li J, Schroeder J, Wall M, Craig S, Poortinga G, Cameron D, Bywater M, Kats L, Gearhart MD, Bardwell VJ, Dickins RA, Hannan RD, Papenfuss AT, Johnstone RW.

Nat Commun. 2017 Mar 6;8:14581. doi: 10.1038/ncomms14581.


Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling.

Quin J, Chan KT, Devlin JR, Cameron DP, Diesch J, Cullinane C, Ahern J, Khot A, Hein N, George AJ, Hannan KM, Poortinga G, Sheppard KE, Khanna KK, Johnstone RW, Drygin D, McArthur GA, Pearson RB, Sanij E, Hannan RD.

Oncotarget. 2016 Aug 2;7(31):49800-49818. doi: 10.18632/oncotarget.10452.


Defining the essential function of FBP/KSRP proteins: Drosophila Psi interacts with the mediator complex to modulate MYC transcription and tissue growth.

Guo L, Zaysteva O, Nie Z, Mitchell NC, Amanda Lee JE, Ware T, Parsons L, Luwor R, Poortinga G, Hannan RD, Levens DL, Quinn LM.

Nucleic Acids Res. 2016 Sep 19;44(16):7646-58. doi: 10.1093/nar/gkw461. Epub 2016 May 20.


Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma.

Devlin JR, Hannan KM, Hein N, Cullinane C, Kusnadi E, Ng PY, George AJ, Shortt J, Bywater MJ, Poortinga G, Sanij E, Kang J, Drygin D, O'Brien S, Johnstone RW, McArthur GA, Hannan RD, Pearson RB.

Cancer Discov. 2016 Jan;6(1):59-70. doi: 10.1158/2159-8290.CD-14-0673. Epub 2015 Oct 21.


S6 Kinase is essential for MYC-dependent rDNA transcription in Drosophila.

Mitchell NC, Tchoubrieva EB, Chahal A, Woods S, Lee A, Lin JI, Parsons L, Jastrzebski K, Poortinga G, Hannan KM, Pearson RB, Hannan RD, Quinn LM.

Cell Signal. 2015 Oct;27(10):2045-53. doi: 10.1016/j.cellsig.2015.07.018. Epub 2015 Jul 26.


Defective Hfp-dependent transcriptional repression of dMYC is fundamental to tissue overgrowth in Drosophila XPB models.

Lee JE, Mitchell NC, Zaytseva O, Chahal A, Mendis P, Cartier-Michaud A, Parsons LM, Poortinga G, Levens DL, Hannan RD, Quinn LM.

Nat Commun. 2015 Jun 15;6:7404. doi: 10.1038/ncomms8404.


A novel role for the Pol I transcription factor UBTF in maintaining genome stability through the regulation of highly transcribed Pol II genes.

Sanij E, Diesch J, Lesmana A, Poortinga G, Hein N, Lidgerwood G, Cameron DP, Ellul J, Goodall GJ, Wong LH, Dhillon AS, Hamdane N, Rothblum LI, Pearson RB, Haviv I, Moss T, Hannan RD.

Genome Res. 2015 Feb;25(2):201-12. doi: 10.1101/gr.176115.114. Epub 2014 Dec 1.


Targeting RNA polymerase I to treat MYC-driven cancer.

Poortinga G, Quinn LM, Hannan RD.

Oncogene. 2015 Jan 22;34(4):403-12. doi: 10.1038/onc.2014.13. Epub 2014 Mar 10. Review.


The mTORC1 inhibitor everolimus prevents and treats Eμ-Myc lymphoma by restoring oncogene-induced senescence.

Wall M, Poortinga G, Stanley KL, Lindemann RK, Bots M, Chan CJ, Bywater MJ, Kinross KM, Astle MV, Waldeck K, Hannan KM, Shortt J, Smyth MJ, Lowe SW, Hannan RD, Pearson RB, Johnstone RW, McArthur GA.

Cancer Discov. 2013 Jan;3(1):82-95. doi: 10.1158/2159-8290.CD-12-0404. Epub 2012 Dec 14.


Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.

Bywater MJ, Poortinga G, Sanij E, Hein N, Peck A, Cullinane C, Wall M, Cluse L, Drygin D, Anderes K, Huser N, Proffitt C, Bliesath J, Haddach M, Schwaebe MK, Ryckman DM, Rice WG, Schmitt C, Lowe SW, Johnstone RW, Pearson RB, McArthur GA, Hannan RD.

Cancer Cell. 2012 Jul 10;22(1):51-65. doi: 10.1016/j.ccr.2012.05.019.


AKT promotes rRNA synthesis and cooperates with c-MYC to stimulate ribosome biogenesis in cancer.

Chan JC, Hannan KM, Riddell K, Ng PY, Peck A, Lee RS, Hung S, Astle MV, Bywater M, Wall M, Poortinga G, Jastrzebski K, Sheppard KE, Hemmings BA, Hall MN, Johnstone RW, McArthur GA, Hannan RD, Pearson RB.

Sci Signal. 2011 Aug 30;4(188):ra56. doi: 10.1126/scisignal.2001754.


c-MYC coordinately regulates ribosomal gene chromatin remodeling and Pol I availability during granulocyte differentiation.

Poortinga G, Wall M, Sanij E, Siwicki K, Ellul J, Brown D, Holloway TP, Hannan RD, McArthur GA.

Nucleic Acids Res. 2011 Apr;39(8):3267-81. doi: 10.1093/nar/gkq1205. Epub 2010 Dec 21.


UBF levels determine the number of active ribosomal RNA genes in mammals.

Sanij E, Poortinga G, Sharkey K, Hung S, Holloway TP, Quin J, Robb E, Wong LH, Thomas WG, Stefanovsky V, Moss T, Rothblum L, Hannan KM, McArthur GA, Pearson RB, Hannan RD.

J Cell Biol. 2008 Dec 29;183(7):1259-74. doi: 10.1083/jcb.200805146. Epub 2008 Dec 22.


Translational control of c-MYC by rapamycin promotes terminal myeloid differentiation.

Wall M, Poortinga G, Hannan KM, Pearson RB, Hannan RD, McArthur GA.

Blood. 2008 Sep 15;112(6):2305-17. doi: 10.1182/blood-2007-09-111856. Epub 2008 Jul 11.


MAD1 and c-MYC regulate UBF and rDNA transcription during granulocyte differentiation.

Poortinga G, Hannan KM, Snelling H, Walkley CR, Jenkins A, Sharkey K, Wall M, Brandenburger Y, Palatsides M, Pearson RB, McArthur GA, Hannan RD.

EMBO J. 2004 Aug 18;23(16):3325-35. Epub 2004 Jul 29.


mTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is mediated by phosphorylation of the carboxy-terminal activation domain of the nucleolar transcription factor UBF.

Hannan KM, Brandenburger Y, Jenkins A, Sharkey K, Cavanaugh A, Rothblum L, Moss T, Poortinga G, McArthur GA, Pearson RB, Hannan RD.

Mol Cell Biol. 2003 Dec;23(23):8862-77.


A network of interacting transcriptional regulators involved in Drosophila neural fate specification revealed by the yeast two-hybrid system.

Alifragis P, Poortinga G, Parkhurst SM, Delidakis C.

Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):13099-104.


Characterization of sequences responsible for trans-inactivation of the Drosophila brown gene.

Martin-Morris LE, Loughney K, Kershisnik EO, Poortinga G, Henikoff S.

Cold Spring Harb Symp Quant Biol. 1993;58:577-84. No abstract available.


Tryptophan analog resistance mutations in Chlamydomonas reinhardtii.

Dutcher SK, Galloway RE, Barclay WR, Poortinga G.

Genetics. 1992 Jul;131(3):593-607.


Reliable standards of care are determined by consensus of those who provide that care.

McMichael RA, Poortinga G, Powell J, Sheely RB, Poteete RD, Sherman RP.

J Manipulative Physiol Ther. 1991 Mar-Apr;14(3):217-21. No abstract available.


Making claims.

Poortinga GP.

J Manipulative Physiol Ther. 1988 Oct;11(5):457-60. No abstract available.


Supplemental Content

Loading ...
Support Center